Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine

World Journal of Gastroenterology

Volumn 20, Issue 22, 2014, Pages 6759-6773

  Saha, Lekha ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Diagnosis; Evidence based medicine; Irritable bowel syndrome; Pathogenesis; Treatment

Indexed keywords

AGI 011; AMITRIPTYLINE; ANTIBIOTIC AGENT; DDP 225; DDP 773; DICYCLOVERINE; EMICERFONT; ERYTHRITOL; FAT; GALACTAN; GTP 010; HYOSCYAMINE; LACTITOL; LINACLOTIDE; LUBIPROSTONE; MANNITOL; PEXACERFONT; PLACEBO; PROKINETIC AGENT; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RAMOSETRON; REZATOMIDINE; SEROTONIN; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SOLABEGRON; SORBITOL; SUGAR ALCOHOL; TOFISOPAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELUSETRAG; XYLITOL; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

ABDOMINAL PAIN; ALTERNATIVE MEDICINE; ARTICLE; BACTERIAL OVERGROWTH; BLOATING; BRAIN FUNCTION; BRAIN GUT INTERACTION; CONSTIPATION; DIARRHEA; DIET THERAPY; DIETARY FIBER; DISEASE CLASSIFICATION; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; EXERCISE; GENETICS; HUMAN; IMMUNITY; INTESTINE FUNCTION; IRRITABLE COLON; LACTOSE INTOLERANCE; MACRONUTRIENT; META ANALYSIS (TOPIC); NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROME III DIAGNOSTIC CRITERIA; SYSTEMATIC REVIEW (TOPIC); IRRITABLE BOWEL SYNDROME; LIFESTYLE; PRACTICE GUIDELINE; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 84902206375     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i22.6759     Document Type: Article

References (107)

1. Drossman DA, Corrazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates, 2006
2. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 344: 1846-1850 [PMID: 11407347 DOI: 10.1056/ NEJM200106143442407]
3. Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg 2012; 25: 46-52 [PMID: 23449495 DOI: 10.1055/s-0032-1301759]
4. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061-2068 [PMID: 11755632 DOI: 10.1016/ S0140-6736(01)07103-3]
5. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-357 [PMID: 15822040 DOI: 10.1016/S1542-3565(04)00726-8]
6. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664 [PMID: 15188158 DOI: 10.1053/ j.gastro.2004.03.013]
7. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131 [PMID: 12454866 DOI: 10.1053/gast.2002.37095]
8. Van Oudenhove L, Vandenberghe J, Demyttenaere K, Tack J. Psychosocial factors, psychiatric illness and functional gastrointestinal disorders: a historical perspective. Digestion 2010; 82: 201-210 [PMID: 20588034 DOI: 10.1159/000269822]
9. Whitehead WE, Burnett CK, Cook EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-2253 [PMID: 8943980 DOI: 10.1007/BF02071408]
10. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-1580 [PMID: 8359066 DOI: 10.1007/BF01303162]
11. World Gastroenterology Organization. Irritable bowel syndrome: a global perspective. World Gastroenterology Organisation Global Guideline 2009. Available from: URL: http://www.jupiterpharma.in/journalpdf/IBS WORLD GASTRO.pdf
12. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004; 53: 666-672 [PMID: 15082584 DOI: 10.1136/gut.2003.021857]
13. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. 2nd ed. McLean, VA: Degnon Associates, 2000
14. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555-564 [PMID: 12241674 DOI: 10.1016/S0140-6736(02)09712-X]
15. Holten KB, Wetherington A, Bankston L. Diagnosing the patient with abdominal pain and altered bowel habits: is it irritable bowel syndrome? Am Fam Physician 2003; 67: 2157-2162 [PMID: 12776965]
16. Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. Intern Med J 2006; 36: 28-36 [PMID: 16409310 DOI: 10.1111/j.1445-5994.2006.01006.x]
17. Locke GR, Zinsmeister AR, Fett SL, Melton LJ, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005; 17: 29-34 [PMID: 15670261 DOI: 10.1111/j.1365-2982.2004.00581.x]
18. Gwee KA. Irritable bowel syndrome in developing countries-a disorder of civilization or colonization? Neurogastroenterol Motil 2005; 17: 317-324 [PMID: 15916618]
19. Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36: 1009-1031 [PMID: 23066886 DOI: 10.1111/apt.12080]
20. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988 [PMID: 19457422 DOI: 10.1053/j.gastro.2009.02.074]
21. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM, Déchelotte P, Coëffier M, Ducrotté P. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7: e42777 [PMID: 23028414 DOI: 10.1371/journal. pone.0042777]
22. Ishihara S, Tada Y, Fukuba N, Oka A, Kusunoki R, Mishima Y, Oshima N, Moriyama I, Yuki T, Kawashima K, Kinoshita Y. Pathogenesis of irritable bowel syndrome--review regarding associated infection and immune activation. Digestion 2013; 87: 204-211 [PMID: 23712295 DOI: 10.1159/000350054]
23. Spiller RC. Effects of serotonin on intestinal secretion and motility. Curr Opin Gastroenterol 2001; 17: 99-103 [PMID: 11224663 DOI: 10.1097/00001574-200103000-00001]
24. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 Suppl 2: 15-30 [PMID: 10429737 DOI: 10.1046/ j.1365-2036.1999.00002.x-i2]
25. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004; 53: 1520-1535 [PMID: 15361507 DOI: 10.1136/gut.2003.035568]
26. Derbyshire SW. A systematic review of neuroimaging data during visceral stimulation. Am J Gastroenterol 2003; 98: 12-20 [PMID: 12526930 DOI: 10.1111/j.1572-0241.2003.07168.x]
27. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 663-670 [PMID: 12692050 DOI: 10.1136/gut.52.5.663]
28. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095-1103 [PMID: 16401691 DOI: 10.1136/gut.2005.077503]
29. McLaughlin J, Houghton LA. The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome. Expert Opin Drug Saf 2006; 5: 313-327 [PMID: 16503751 DOI: 10.1517/14740338.5.2.313]
30. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Lüchinger S, Bertold R, Maecke H, Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-1751 [PMID: 11683688 DOI: 10.1046/j.1365-2036.2001.01103.x]
31. Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 2003; 4: 2089-2098 [PMID: 14596662 DOI: 10.1517/14656566.4.11.2089]
32. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 775-782 [PMID: 10848662 DOI: 10.1046/j.1365-2036.2000.00762.x]
33. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-855 [PMID: 9768527 DOI: 10.1046/ j.1365-2036.1998.00375.x]
34. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011; 9: 461-49; quiz e59 [PMID: 21397724 DOI: 10.1016/j.cgh.2011.02.030]
35. Koloski NA, Talley NJ, Boyce PM. A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: the role of other psychosocial variables. Digestion 2005; 72: 86-96 [PMID: 16127275 DOI: 10.1159/000087722]
36. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000; 47: 861-869 [PMID: 11076888 DOI: 10.1136/gut.47.6.861]
37. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-293 [PMID: 8020671]
38. Mayer EA, Naliboff BD, Craig AD. Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 2006; 131: 1925-1942 [PMID: 17188960 DOI: 10.1053/j.gastro.2006.10.026]
39. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398-409 [PMID: 15911167 DOI: 10.1016/j.pain.2005.03.023]
40. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-607 [PMID: 15831901 DOI: 10.1136/ gut.2004.047423]
41. Saito YA, Petersen GM, Locke GR, Talley NJ. The genetics of irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 1057-1065 [PMID: 16271334 DOI: 10.1016/S1542-3565(05)00184-9]
42. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653-654 [PMID: 698649 DOI: 10.1136/bmj.2.6138.653]
43. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1: S1-35 [PMID: 19521341 DOI: 10.1038/ajg.2008.122]
44. Kruis W, Thieme C, Weinzierl M, Schüssler P, Holl J, Paulus W. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7 [PMID: 6724251]
45. Whitehead WE, Drossman DA. Validation of symptombased diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol 2010; 105: 814-20; quiz 813, 821 [PMID: 20179688 DOI: 10.1038/ajg.2010.56]
46. Engsbro AL, Begtrup LM, Kjeldsen J, Larsen PV, de Muckadell OS, Jarbøl DE, Bytzer P. Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care. Am J Gastroenterol 2013; 108: 972-980 [PMID: 23419383 DOI: 10.1038/ ajg.2013.15]
47. Sanders DS, Carter MJ, Hurlstone DP, Pearce A, Ward AM, McAlindon ME, Lobo AJ. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001; 358: 1504-1508 [PMID: 11705563 DOI: 10.1016/S0140-6736(01)06581-3]
48. Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, Shepherd SJ, Muir JG, Gibson PR. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106: 508-14; quiz 515 [PMID: 21224837 DOI: 10.1038/ajg.2010.487]
49. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995; 122: 107-112 [PMID: 7992984 DOI: 10.7326/0003-4819-122-2-199501150-00005]
50. Drossman DA. Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med 1995; 123: 688-697 [PMID: 7574225 DOI: 10.7326/0003-4819-1 23-9-199511010-00008]
51. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987; 1: 963-965 [PMID: 2882351 DOI: 10.1016/S0140-6736(87)90304-7]
52. Yoon SL, Grundmann O, Koepp L, Farrell L. Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. Altern Med Rev 2011; 16: 134-151 [PMID: 21649455]
53. Hussain Z, Quigley EM. Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 465-471 [PMID: 16441466 DOI: 10.1111/j.1365-2036.2006.02776.x]
54. Liu JP, Yang M, Liu YX, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; (1): CD004116 [PMID: 16437473]
55. Park HJ, Jarrett M, Cain K, Heitkemper M. Psychological distress and GI symptoms are related to severity of bloating in women with irritable bowel syndrome. Res Nurs Health 2008; 31: 98-107 [PMID: 18181134 DOI: 10.1002/nur.20237]
56. Blanchard EB, Lackner JM, Jaccard J, Rowell D, Carosella AM, Powell C, Sanders K, Krasner S, Kuhn E. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res 2008; 64: 119-128 [PMID: 18222125 DOI: 10.1016/ j.jpsychores.2007.10.010]
57. Choung RS, Locke GR, Zinsmeister AR, Schleck CD, Talley NJ. Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol 2009; 104: 1772-1779 [PMID: 19491833 DOI: 10.1038/ajg.2009.239]
58. Hertig VL, Cain KC, Jarrett ME, Burr RL, Heitkemper MM. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res 2007; 56: 399-406 [PMID: 18004186 DOI: 10.1097/01.NNR.0000299855.60053.88]
59. van der Veek PP, van Rood YR, Masclee AA. Clinical trial: short-and long-term benefit of relaxation training for irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 943-952 [PMID: 17767479 DOI: 10.1111/j.1365-2036.2007.03437.x]
60. Zhou EH, Liu HR, Wu HG, Shi Y, Wang XM, Tan LY, Yao LQ, Zhong YS, Jiang Y, Zhang LL. Suspended moxibustion relieves chronic visceral hyperalgesia via serotonin pathway in the colon. Neurosci Lett 2009; 451: 144-147 [PMID: 19114087 DOI: 10.1016/j.neulet.2008.12.026]
61. Tian SL, Wang XY, Ding GH. Repeated electro-acupuncture attenuates chronic visceral hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat irritable bowel syndrome model. Life Sci 2008; 83: 356-363 [PMID: 18694764 DOI: 10.1016/j.lfs.2008.06.027]
62. Schneider A, Weiland C, Enck P, Joos S, Streitberger K, Maser-Gluth C, Zipfel S, Bagheri S, Herzog W, Friederich HC. Neuroendocrinological effects of acupuncture treatment in patients with irritable bowel syndrome. Complement Ther Med 2007; 15: 255-263 [PMID: 18054727 DOI: 10.1016/ j.ctim.2006.12.002]
63. Ma XP, Tan LY, Yang Y, Wu HG, Jiang B, Liu HR, Yang L. Effect of electro-acupuncture on substance P, its receptor and corticotropin-releasing hormone in rats with irritable bowel syndrome. World J Gastroenterol 2009; 15: 5211-5217 [PMID: 19891022 DOI: 10.3748/wjg.15.5211]
64. Sigaeva VA, Malinina EA, Gaziev AI. [Formation of UV-induced DNA-protein cross-links in bacterial cells and the potentials for their elimination]. Radiobiologiia 1981; 21: 568-571 [PMID: 7029608]
65. Kim YJ, Ban DJ. Prevalence of irritable bowel syndrome, influence of lifestyle factors and bowel habits in Korean college students. Int J Nurs Stud 2005; 42: 247-254 [PMID: 15708012 DOI: 10.1016/j.ijnurstu.2004.06.015]
66. Lustyk MK, Jarrett ME, Bennett JC, Heitkemper MM. Does a physically active lifestyle improve symptoms in women with irritable bowel syndrome? Gastroenterol Nurs 2001; 24: 129-137 [PMID: 11847862 DOI: 10.1097/00001610-200105000-00007]
67. Kuttner L, Chambers CT, Hardial J, Israel DM, Jacobson K, Evans K. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res Manag 2006; 11: 217-223 [PMID: 17149454]
68. van Tilburg MA, Palsson OS, Levy RL, Feld AD, Turner MJ, Drossman DA, Whitehead WE. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med 2008; 8: 46 [PMID: 18652682]
69. Taneja I, Deepak KK, Poojary G, Acharya IN, Pandey RM, Sharma MP. Yogic versus conventional treatment in diarrhea-predominant irritable bowel syndrome: a randomized control study. Appl Psychophysiol Biofeedback 2004; 29: 19-33 [PMID: 15077462]
70. Harris LR, Roberts L. Treatments for irritable bowel syndrome: patients' attitudes and acceptability. BMC Complement Altern Med 2008; 8: 65 [PMID: 19099570 DOI: 10.1186/1472-6882-8-65]
71. Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 2009; 109: 1204-1214 [PMID: 19559137 DOI: 10.1016/j.jada.2009.04.012]
72. Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol Clin North Am 2005; 34: 247-255 [PMID: 15862933 DOI: 10.1016/j.gtc.2005.02.005]
73. Daley AJ, Grimmett C, Roberts L, Wilson S, Fatek M, Roalfe A, Singh S. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med 2008; 29: 778-782 [PMID: 18461499 DOI: 10.1055/s-2008-1038600]
74. Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 2005; 3: 992-996 [PMID: 16234045 DOI: 10.1016/S1542-3565(05)00696-8]
75. Villoria A, Serra J, Azpiroz F, Malagelada JR. Physical activity and intestinal gas clearance in patients with bloating. Am J Gastroenterol 2006; 101: 2552-2557 [PMID: 17029608 DOI: 10.1111/j.1572-0241.2006.00873.x]
76. Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol Clin North Am 2005; 34: 205-20, vi [PMID: 15862930 DOI: 10.1016/j.gtc.2005.03.001]
77. Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr 2006; 25: 514-522 [PMID: 17229899 DOI: 10.1080/07315724.2006.10719 567]
78. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, Smith S, Gibson PR, Muir JG. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1366-1373 [PMID: 20659225 DOI: 10.1111/j.1440-1746.2010.06370.x]
79. Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 245-251 [PMID: 14984370 DOI: 10.1111/ j.0269-2813.2004.01862.x]
80. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313 [PMID: 19008265 DOI: 10.1136/bmj.a2313]
81. Saberi-Firoozi M, Khademolhosseini F, Mehrabani D, Yousefi M, Salehi M, Heidary ST. Subjective lactose intolerance in apparently healthy adults in southern Iran: Is it related to irritable bowel syndrome? Indian J Med Sci 2007; 61: 591-597 [PMID: 18025745 DOI: 10.4103/0019-5359.37045]
82. Gupta D, Ghoshal UC, Misra A, Misra A, Choudhuri G, Singh K. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol 2007; 22: 2261-2265 [PMID: 17559357 DOI: 10.1111/j.1440-1746.2007.04986.x]
83. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012; 345: e5836 [PMID: 22951548 DOI: 10.1136/bmj.e5836]
84. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-147 [PMID: 10896640 DOI: 10.7326/0003-4819-133-2-2000 07180-00013]
85. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48: 272-282 [PMID: 11156653 DOI: 10.1136/gut.48.2.272]
86. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 750-758 [PMID: 12738451 DOI: 10.1111/j.1572-0241.2003.07306.x]
87. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-361 [PMID: 11207510 DOI: 10.1046/j.1365-2036.2001.00937.x]
88. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981; 3: 153-156 [PMID: 7016973 DOI: 10.1097/0 0004836-198106000-00009]
89. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40: 86-95 [PMID: 7821126 DOI: 10.1007/BF02063948]
90. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112: 1714-1743 [PMID: 9136853 DOI: 10.1016/S0016-5085(97)70056-8]
91. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8: 409-416 [PMID: 7986966 DOI: 10.1111/ j.1365-2036.1994.tb00308.x]
92. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-378 [PMID: 19001059 DOI: 10.1136/ gut.2008.163162]
93. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344: 39-40 [PMID: 7912305 DOI: 10.1016/S0140-6736(94)91055-3]
94. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: S7-26 [PMID: 12425586 DOI: 10.1016/S0002-9270(02)05657-5]
95. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009; 339: b3154 [PMID: 19713235 DOI: 10.1136/ bmj.b3154]
96. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-341 [PMID: 19006537 DOI: 10.1111/ j.1365-2036.2008.03881.x]
97. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819-827 [PMID: 7720476 DOI: 10.1007/BF02064986]
98. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506 [PMID: 11151884 DOI: 10.1111/j.1572-0241.2000.03368.x]
99. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebocontrolled study. Am J Gastroenterol 2003; 98: 412-419 [PMID: 12591062]
100. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32 [PMID: 21208106 DOI: 10.1056/NEJMoa1004409]
101. Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163: 265-274 [PMID: 12578506 DOI: 10.1001/ archinte.163.3.265]
102. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55: 1385-1390 [PMID: 19507027 DOI: 10.1007/s10620-009-0854-9]
103. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007; 39: 530-536 [PMID: 17420159 DOI: 10.1016/j.dld.2007.02.006]
104. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-149; quiz 1050 [PMID: 19277023 DOI: 10.1038/ajg.2009.25]
105. Gaylord SA, Palsson OS, Garland EL, Faurot KR, Coble RS, Mann JD, Frey W, Leniek K, Whitehead WE. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol 2011; 106: 1678-1688 [PMID: 21691341 DOI: 10.1038/ ajg.2011.184]
106. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-660 [PMID: 10982758 DOI: 10.1053/gast.2000.16484]
107. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724-735 [PMID: 3393032]